Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Abstract Background The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherap...

Full description

Bibliographic Details
Main Authors: Houda Bahig, Francine Aubin, John Stagg, Olguta Gologan, Olivier Ballivy, Eric Bissada, Felix-Phuc Nguyen-Tan, Denis Soulières, Louis Guertin, Edith Filion, Apostolos Christopoulos, Louise Lambert, Mustapha Tehfe, Tareck Ayad, Danielle Charpentier, Rahima Jamal, Philip Wong
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Head and neck cancer
Metastatic
Immunotherapy
SBRT
Durvalumab
Tremelimumab
Online Access:http://link.springer.com/article/10.1186/s12885-019-5266-4

Internet

http://link.springer.com/article/10.1186/s12885-019-5266-4

Similar Items